CN111228389A - Application of aloe catharsis capsule in preparing medicine for preventing and treating abdominal distension - Google Patents
Application of aloe catharsis capsule in preparing medicine for preventing and treating abdominal distension Download PDFInfo
- Publication number
- CN111228389A CN111228389A CN202010232679.2A CN202010232679A CN111228389A CN 111228389 A CN111228389 A CN 111228389A CN 202010232679 A CN202010232679 A CN 202010232679A CN 111228389 A CN111228389 A CN 111228389A
- Authority
- CN
- China
- Prior art keywords
- abdominal distension
- aloe
- parts
- abdominal
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicines, relates to application of a traditional Chinese medicine composition, and particularly relates to application of a aloe catharsis capsule in preparation of a medicine for preventing and treating abdominal distension. The results of pharmacodynamic tests and clinical tests show that: the composition provided by the invention has a remarkable treatment effect on abdominal distension caused by functional dyspepsia and abdominal distension after an abdominal operation, has a definite curative effect and a comprehensive effect when treating various abdominal distension, has the characteristics of safety and no toxicity, and can play a role in comprehensively conditioning abdominal distension patients while treating the abdominal distension.
Description
Technical Field
The invention belongs to the field of medicines, relates to application of a traditional Chinese medicine composition, and particularly relates to application of a aloe catharsis capsule in preparation of a medicine for preventing and treating abdominal distension.
Background
Abdominal distension is a common condition in daily life, and almost everyone experiences abdominal distension. Although abdominal distension is a small disease, the abdominal distension is very uncomfortable and even affects diet and sleep severely. The causes of abdominal distension include functional dyspepsia, disease, abdominal operation, etc., wherein the functional dyspepsia refers to a group of clinical syndromes that are persistent or recurrent in addition to the constitutional diseases, epigastric pain, postprandial fullness, abdominal distension, belching, early satiety, anorexia, nausea, and other epigastric discomfort symptoms, the chronic period is more than 3 months (sometimes, the course of disease is more than 1 month), and the functional dyspepsia is called when no abnormality is found by gastroscopy, upper gastrointestinal barium meal radiography, and abdominal B-ultrasonography. The traditional Chinese medicine holds that the spleen governs transportation and transformation and is the most important physiological function of the spleen. The normal condition of spleen governing transportation and transformation (spleen qi) is the guarantee of normal physiological functions of spleen transportation and spleen transformation. The spleen-qi deficiency (spleen deficiency syndrome) is the basis of the pathology of "failure of transportation" and "failure" of the spleen, and functional dyspepsia corresponds to the "failure of transportation" of the spleen. Long-term abdominal distension can severely affect the mental state of a patient and can lead to wasting of the patient, severely affecting the quality of life of the patient.
Abdominal distension caused by abdominal operation is very common in daily life, the operation is still the main treatment means for treating surgical diseases at present, and various complications can occur after the operation no matter the traditional open operation or the current popular laparoscopic operation, so that the postoperative complications cannot be absolutely avoided, and the occurrence rate can be reduced to the minimum. Abdominal distension is a common complication of surgical abdominal operations, and the incidence rate of abdominal distension accounts for about 8% -28% of postoperative complications. Along with the understanding of postoperative abdominal distension is deepened continuously in recent years, the condition that the abdominal distension appears after the operation in each major hospital surgery is very important, although the treatment to postoperative abdominal distension no matter be traditional Chinese medicine or western medicine can both obtain certain effect, because the reason of postoperative abdominal distension is comparatively complicated, in addition the characteristics of postoperative patient weak constitution, if can find a medicine that the side effect is little and can carry out all-round recuperation to the multiple reason of abdominal distension, help when solving the abdominal distension problem resumes patient's bodily function, will very big alleviate abdominal operation patient's postoperative misery.
Disclosure of Invention
The invention mainly aims to provide application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating abdominal distension. Mainly aims at the new indications developed by the marketed product 'Yuhui Tongbiang capsule'. The formula patent of the product of the aloe laxative capsule is CN100453105C, and the patent name is that a composition with the functions of relaxing bowels, expelling toxin, losing weight and reducing fat and a preparation method thereof are authorized.
The purpose of the invention is mainly realized by the following technical scheme:
the results of the study on the therapeutic effect of the composition of the efficacy examples on the abdominal distension caused by functional dyspepsia show that: the traditional Chinese medicine composition provided by the invention can obviously improve abdominal distension caused by functional dyspepsia, and can obviously improve ulcer and bleeding states of stomach and intestines, so that the gastrointestinal content state is recovered to be normal, and the problem of abdominal distension caused by functional dyspepsia is fundamentally and comprehensively solved.
Clinical example 1 and clinical example 2 show that: the composition provided by the invention has a remarkable treatment effect on acute abdominal distension induced by cold or overeating uncooked and cold food and greasiness and abdominal distension after laparoscopic surgery, is beneficial to relieving other postoperative complications while treating abdominal distension after laparoscopic surgery, and is beneficial to recovery of a body of a patient after surgery.
The Chinese medicinal composition is prepared from Polygoni Multiflori radix, Aloe, semen Cassiae, fructus Lycii, colla Corii Asini, Ginseng radix, Atractylodis rhizoma and fructus Aurantii Immaturus as raw materials.
The composition comprises the following components in parts by weight: 60-150 parts of polygonum multiflorum, 100 parts of aloe, 80-180 parts of cassia seed, 30-150 parts of medlar, 30-150 parts of donkey-hide gelatin, 20-100 parts of ginseng, 20-100 parts of bighead atractylodes rhizome, 50-200 parts of immature bitter orange, preferably: 120 parts of polygonum multiflorum, 160 parts of aloe, 140 parts of cassia seed, 75 parts of wolfberry fruit, 75 parts of donkey-hide gelatin, 50 parts of ginseng, 50 parts of bighead atractylodes rhizome and 120 parts of immature bitter orange.
The components in the composition are prepared according to the patent CN100453105C, the composition with the functions of relaxing bowels, expelling toxin, losing weight and reducing fat and the preparation method or the extraction method of the components.
The traditional Chinese medicine composition provided by the invention can also contain pharmaceutically acceptable auxiliary materials, and the traditional Chinese medicine composition is prepared into a medicinal preparation according to a conventional preparation process, such as: pill, tablet, granule, capsule, oral liquid, unguent, emulsion, chewable agent and injection.
Preferably tablets, capsules and granules.
The preparation can achieve the same treatment effect as the traditional Chinese medicine composition provided by the invention when being applied to the prevention and treatment of abdominal distension.
The application of the composition in preparing medicines for preventing and treating abdominal distension.
The abdominal distension is the abdominal distension caused by functional dyspepsia, diseases, abdominal operation or medicines, wherein the diseases are ulcers, tumors or liver diseases and also include the abdominal distension caused by tumor radiotherapy and chemotherapy; the abdominal operation is an open operation or a laparoscopic operation.
The abdominal distension is acute abdominal distension, preferably acute abdominal distension caused by cold, food retention and qi generation.
The dosage of the Chinese medicinal composition for preventing and treating abdominal distention is 1mg/kg.d-100mg/kg.d, preferably 20 mg/kg.d.
Compared with the existing medicine for treating abdominal distension, the traditional Chinese medicine composition provided by the invention has the following advantages when used for treating abdominal distension:
1. has definite curative effect and comprehensive action
The traditional Chinese medicine composition provided by the invention can obviously improve abdominal distension caused by functional dyspepsia and abdominal distension after an abdominal operation, has obvious treatment effects on acute abdominal distension, abdominal distension caused by diseases and medicines, and has definite treatment effect and comprehensive effect when the abdominal distension is treated.
2. Safe, nontoxic and comprehensive conditioning
The traditional Chinese medicine composition provided by the invention has the characteristics of safety and no toxicity, can be used for treating abdominal distension and simultaneously remarkably improving the emaciation state of a patient with functional dyspepsia, is beneficial to reducing postoperative complications of the patient and helping the recovery of the physical function of the patient, and can play a role in comprehensively conditioning while treating abdominal distension.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention is further illustrated below by specific examples in order to provide those skilled in the art with a full understanding of the present invention, but it should be understood by those skilled in the art that the examples of the present invention are not to be construed as limiting the present invention in any way.
Pharmacodynamic example 1 therapeutic action of the composition on abdominal distension caused by functional dyspepsia
The traditional Chinese medicine symptoms of functional dyspepsia comprise spleen deficiency, spleen and kidney qi deficiency, liver stagnation and spleen deficiency, spleen deficiency and dampness stagnation, cold and heat mixed syndrome, and spleen yang deficiency. The most spleen deficiency syndrome is observed, the viscera involved in functional dyspepsia are mainly the spleen, and the kidney and liver are the secondary ones. According to the theories of 'visceral sensitivity is increased due to inflammation' and 'spleen is injured due to overstrain', the invention adopts a compound small platform standing method of iodoacetamide sucrose solution gastric perfusion to prepare an animal model of functional dyspepsia and spleen deficiency syndrome with visceral sensitivity increased, and is used for researching the treatment effect of the traditional Chinese medicine composition on abdominal distension caused by functional dyspepsia.
1 Material
1.1 animals
Healthy male Wistar rats 90, clean grade, born 6 d.
1.2 feed
The basic formula feed comprises the components of 18% of casein, 58.8% of starch, 10% of sucrose, 5% of corn oil, 3% of cellulose, 1% of vitamin, 4% of inorganic salt and 0.2% of DL methionine.
1.3 reagents
2% sucrose solution, 0.1% iodoacetamide sucrose solution, and motilin kit.
1.4 apparatus
A self-made small platform standing box is characterized in that 15 small platforms (the diameter of the platform is 8 cm and the height of the platform is 10 cm) are arranged in a square water tank (112 cm is multiplied by 62 cm is multiplied by 41 cm), the periphery of the platforms is filled with water, the water depth is 1.5 cm, and the water temperature is maintained at (22 +/-2) DEG C. High-speed refrigerated centrifuge, electronic balance, and microplate reader.
2 moulding and grouping
Adaptively feeding 6d born rats with 10 rats per cage and 1 mother rat, and after adaptive feeding for 4d, dividing the rats into a normal group and a modeling group, wherein 30 rats in the normal group are subjected to intragastric administration of 2% sucrose solution and each rat is subjected to 0.2 mL; the number of the molding die is 60, the stomach is irrigated with 0.1 percent of iodoacetamide sucrose solution, and the volume is 0.2 mL/die. Weaning each rat at 3 weeks of age, separating the rats into cages, carrying out continuous molding on 3-4 rats/cage for 6 days, and normally feeding the rats.
Randomly dividing model-making rats into model composite small platformsThe groups and the traditional Chinese medicine composition groups are 30 in each group, and two groups of rats are stood on a small platform at 7: 00-17: 00 every day and are continuously molded for 14 d. The traditional Chinese medicine composition (120 mg.kg) provided by the invention is administrated by intragastric administration in the traditional Chinese medicine composition group during the molding period－1) And (3) the gastric perfusion of the model composite small platform group is performed with physiological saline with the same volume, and the perfusion lasts for 2 weeks after the molding is finished.
3 observation index
3.1 general case
Food intake, water intake, body weight, activity status, color and luster of hair, and feces condition.
3.2 measurement of serum motilin
After the last administration, the abdominal aorta was bled, and serum was collected by high speed centrifugation and assayed for motilin in serum using an ELISA kit.
3.3 comparison of Abdominal distension in rats in groups
After the last administration, each group of rats was anesthetized and dissected to observe the swelling condition of the stomach and intestine and the shape of the content.
4 statistical methods
Data are statistically processed by SPSS 17.0 software, data in normal distribution are analyzed by single-factor variance, quantitative data are represented by mean +/-standard deviation (x +/-s), comparison among groups is performed by t test, and difference P smaller than 0.05 has statistical significance.
5 results of the test
5.1 general case comparison
The normal rats have glossy back hair, lively and well-moving back hair and faster weight increase, while the rats in the model compound small platform group have a series of spleen deficiency syndrome related symptoms such as fatigue, sleepiness, laziness, lusterless hair, soft stool and the like, and compared with the rats in the model compound small platform group, the rats in the traditional Chinese medicine composition have obviously lighter symptoms.
The body weight comparison of the rats in each group is shown in Table 1.
As can be seen from the above table, at 0 week (end of molding), the weight of the model composite small platform group is significantly different from that of the normal group, indicating that molding is successful; compared with the small model composite platform group, the traditional Chinese medicine composition has significant difference in body weight at the end of model building and in the subsequent two-week continuous administration process, which shows that the traditional Chinese medicine composition provided by the invention has significant prevention and treatment effects on functional dyspepsia, can obviously improve emaciation caused by functional dyspepsia and abdominal distension, and can comprehensively condition functional dyspepsia rats by combining with the general conditions of rats, thereby improving the mental state of abdominal distension rats.
5.2 serum motilin comparison
The comparison of serum motilin in rats of each group is shown in table 2.
As can be seen from the above table, the content of motilin in serum of the model composite small platform group is significantly different from that of the normal group, which indicates that the model building is successful; compared with the model composite small platform group, the traditional Chinese medicine composition group has significant difference in serum motilin content, and shows that the traditional Chinese medicine composition provided by the invention can significantly improve the serum motilin content and accelerate gastric emptying, so that the problem of abdominal distension caused by functional dyspepsia is solved.
5.3 comparison of the swelling of stomach and intestine of rats
The rats in the normal group have no gastric and intestinal swelling and have normal shapes of gastric and intestinal contents; the rats in the model compound small platform group have obvious stomach swelling, serious shedding of gastric mucosa and some ulcer spots; the small intestine is filled with gas, some small intestines have thin contents, part of intestinal walls bleed seriously, and some rat intestinal walls have obvious edema; the cecum is highly aerated, and most of the contents are dry and hard; the colon and rectum are mostly filled with a peptone sample and the intestinal wall is highly edematous. Compared with the model compound small platform group, the traditional Chinese medicine composition group has no obvious swelling and distension of the stomach and the intestine, only the stomach of individual rats has slight swelling, the stomach has no ulcer phenomenon, the intestinal part has no bleeding phenomenon, and the shape of gastrointestinal contents is normal.
The above results show that: the traditional Chinese medicine composition provided by the invention can obviously improve abdominal distension caused by functional dyspepsia, and can obviously improve ulcer and bleeding states of stomach and intestines, so that the gastrointestinal content state is recovered to be normal, and the problem of abdominal distension caused by functional dyspepsia is fundamentally and comprehensively solved.
Clinical example 1 therapeutic effect of composition on acute abdominal distention
1 data and method
1.1 general data
The observed objects are all people who suffer from cold or have eaten raw or cold food and are greasy to induce epigastric distending pain and discomfort with poor appetite and nausea, people who can relieve the symptoms after the primary disease of treatment such as cardiovascular and cerebrovascular diseases, ketoacidosis, liver and gall, pancreas and kidney diseases, surgical acute abdomen diseases and the like are excluded, 20 cases of functional dyspepsia are diagnosed through gastroscopy or barium meal fluoroscopy, 18 cases of gastritis, 16 cases of gastric ulcer and 22 cases of duodenal ulcer are randomly divided into 2 groups by a coin feeding method before treatment, 38 cases of treatment groups and 38 cases of control groups, and the disease conditions and the ages of the two groups have no obvious difference.
1.2 methods of treatment
The two groups are administered with acid-inhibiting, gastric mucosa protecting, anti-infection, nutrition supporting and symptomatic treatment according to the disease condition and examination result, 500 mg of the composition is orally administered to a treatment group every time, three times a day, 10mg of molting tablets is administered to a control group, 5mg of mosapride tablets is administered to a patient with constipation, three times a day, and the curative effect is evaluated after 3 days of treatment.
1.3 criteria for efficacy assessment
When the abdominal distention, abdominal pain, nausea and vomiting disappear;
has obvious effects of relieving epigastric distending pain without nausea and vomiting;
the medicine has the advantages that the symptoms are obviously relieved;
no effect, no significant reduction of the above symptoms.
1.4 statistical treatment
X2Test, test level α = 0.05.
2 results
The results of the two groups of treatments are shown in table 3, the treatment group has the significant efficiency of 92.1 percent in 3 days and is obviously superior to the control group (78.9 percent), and the results fully show that: the traditional Chinese medicine composition provided by the invention has an obvious treatment effect on acute abdominal distension induced by cold catching or overeating uncooked coldness and greasiness, and the effect is obviously superior to that of molting.
Clinical example 2 therapeutic Effect of the composition on Abdominal distension after laparoscopy
1 data and method
1.1 general data
80 cases of patients who undergo laparoscopic surgery and are collected in 2016 to 2018 and 4 are selected as study objects, and the study objects are divided into a control group and an observation group according to different postoperative care modes, wherein 40 cases of the patients are selected. 22 men and 18 women in the control group; age 28-69 years, mean (40.1 ± 8.9) years; observing 20 men and 20 women in the group; the age was 22-72 years, with the mean (41.3. + -. 10.2) years. The difference between the two groups of patients in sex ratio, age and operation position comparison is not statistically significant (P is more than 0.05), and the two groups of patients have comparability.
1.2 methods
1.2.1 the control group was given routine care, and patients were educated on health after admission and informed in advance that abdominal distension may occur after surgery, but there were also relevant methods and measures to prevent abdominal distension, let patients reassure, and relieve preoperative stress. Training the ability of patients to cough, expectorate and turn over in bed, and informing the patients to relieve the bowels in bed. After the operation, the patient is guided to eat and is informed to take liquid diet and semiliquid diet as main materials and gradually transit, thereby avoiding eating starch, milk, bean products and the like, aggravating the flatulence of the patient, listening to the question of the patient with patience and solving the problem of the patient with patience.
1.2.2 Observation group on the basis of the above, 500 mg of the traditional Chinese medicine composition provided by the invention is administered once, three times a day.
1.3 Observation index
1.3.1 record of anus exhaust time and bowel sound recovery time
And (3) counting anus exhaust time and bowel sound recovery time after operation of two groups of patients, and taking the patient chief complaint exhaust recording time and chief complaint bowel sound recovery time which is 5 times per minute as a reference standard.
1.3.2 Abdominal distension statistics
The occurrence of abdominal distension is recorded, with the following specific criteria:
no abdominal distension: the abdomen of the patient is soft and flat after the operation and has no pressure pain;
mild abdominal distension: the abdomen of the patient is flat after operation and has pressure pain;
moderate abdominal distension: the abdomen of the patient is slightly raised after the operation and has pressure pain;
severe abdominal distension: the abdomen of the patient is swollen after the operation, and the tenderness is obvious.
1.3.3 statistics of the numbness of limbs and the recovery of the body after the operation of two groups of patients.
1.4 statistical methods
The data were analyzed using SPSS19.0 statistical software, where the counts are expressed in n (%) and comparisons between groups are by X%2Checking; the data are expressed as (χ. + -.s), the comparison between groups is performed by t-test, and the result is expressed as P < 0.05, indicating that the difference is statistically significant.
2 results
2.1 comparison of exsufflation time and borborygmus recovery time in two groups of patients
The anal exhaustion time and bowel sound recovery time ratio for both groups of patients is shown in table 4, from which it can be seen that both the anal exhaustion time and bowel sound recovery time of the observation group are shorter than those of the control group, and the comparison shows significant differences (p < 0.01).
2.2 comparison of postoperative Abdominal distension in two groups of patients
A comparison of postoperative bloating in both groups of patients is shown in table 5, from which it can be seen that the observed bloating rate was significantly lower than the control (p < 0.01).
2.3 comparison of numbness of limbs and recovery of body after operation
Through observation and record after operation, the following results are found: in the control group, 4 patients have numbness of limbs, and the occurrence rate is 10%; the observation group has no phenomenon, and compared with the control group, the wound healing condition of patients in the observation group is better, the getting-off time is earlier, and the recovery condition of the whole body is obviously better than that of the control group.
The above results show that: the composition provided by the invention not only has a remarkable treatment effect on postoperative abdominal distension, but also is beneficial to relieving other postoperative complications and is beneficial to the recovery of postoperative bodies of patients.
Claims (10)
1. The application of the aloe cathartic in preparing the medicine for preventing and treating abdominal distension is characterized in that the aloe cathartic is prepared by taking polygonum multiflorum, aloe, cassia seed, medlar, donkey-hide gelatin, ginseng, largehead atractylodes rhizome and immature bitter orange as raw materials.
2. The use of claim 1, wherein the fleece-flower root, the aloe, the cassia seed, the medlar, the donkey-hide gelatin, the ginseng, the largehead atractylodes rhizome and the immature bitter orange are calculated according to the following weight portions: 60-150 parts of polygonum multiflorum, 200 parts of aloe 100-.
3. The use of claim 2, wherein the fleece-flower root, the aloe, the cassia seed, the medlar, the donkey-hide gelatin, the ginseng, the largehead atractylodes rhizome and the immature bitter orange are calculated according to the following weight portions: 120 parts of polygonum multiflorum, 160 parts of aloe, 140 parts of cassia seed, 75 parts of medlar, 75 parts of donkey-hide gelatin, 50 parts of ginseng, 50 parts of atractylodes macrocephala and 120 parts of immature bitter orange.
4. The use according to claims 1-3, wherein said aloe vera laxative further comprises pharmaceutically acceptable excipients.
5. A laxative drug containing the aloe vera of claim 4, wherein the drug is in the form of tablets, capsules or granules.
6. The use according to claim 1, wherein the abdominal distension is an abdominal distension caused by functional dyspepsia, a disease, abdominal surgery or a drug.
7. The use according to claim 6, wherein the disease is a gastric, intestinal ulcer, tumor or liver disease.
8. Use according to claim 6, wherein the abdominal surgery is open surgery or laparoscopic surgery.
9. Use according to claim 1, wherein the abdominal distension is acute abdominal distension, preferably acute abdominal distension caused by cold, food retention, or gas production.
10. Use according to claim 1, wherein the alocathartic is administered in an amount of 1mg/kg.d to 100mg/kg.d, preferably 20mg/kg.d, for the prevention and treatment of bloating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010232679.2A CN111228389A (en) | 2020-03-28 | 2020-03-28 | Application of aloe catharsis capsule in preparing medicine for preventing and treating abdominal distension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010232679.2A CN111228389A (en) | 2020-03-28 | 2020-03-28 | Application of aloe catharsis capsule in preparing medicine for preventing and treating abdominal distension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111228389A true CN111228389A (en) | 2020-06-05 |
Family
ID=70869985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010232679.2A Pending CN111228389A (en) | 2020-03-28 | 2020-03-28 | Application of aloe catharsis capsule in preparing medicine for preventing and treating abdominal distension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111228389A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113332373A (en) * | 2021-07-14 | 2021-09-03 | 鲁南制药集团股份有限公司 | Application of aloe cathartic preparation in preparing medicine for treating vomiting |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1748765A (en) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
-
2020
- 2020-03-28 CN CN202010232679.2A patent/CN111228389A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1748765A (en) * | 2004-09-17 | 2006-03-22 | 鲁南制药集团股份有限公司 | Composition with catharsis and toxin expelling, fat reducing and weight reducing function and preparing method |
Non-Patent Citations (3)
| Title |
|---|
| 周佳宝: "首荟通便胶囊治疗老年功能性便秘的疗效观察", 中国全科医学, vol. 22, no. 2, pages 149 - 151 * |
| 大千网: "治疗腹胀便溏的药", pages 1 - 3, Retrieved from the Internet <URL:http://www.178yy.com/bx/yyjk/513/3286460.html> * |
| 大千网: "首荟通便的功效与作用", pages 1, Retrieved from the Internet <URL:http://www.178yy.com/bx/yyjk/502/2640046.html> * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113332373A (en) * | 2021-07-14 | 2021-09-03 | 鲁南制药集团股份有限公司 | Application of aloe cathartic preparation in preparing medicine for treating vomiting |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100998843A (en) | Medicinal composition for treating cholecystitis | |
| CN103690919B (en) | Medicine being used for the treatment of piglet iron-deficiency anemia and preparation method thereof | |
| CN110178906A (en) | A kind of strengthen immunity improves the decline of chemotherapy blood picture, liver and the impaired food compositions and its preparation process of gastrointestinal tract | |
| CN111228389A (en) | Application of aloe catharsis capsule in preparing medicine for preventing and treating abdominal distension | |
| CN102580048A (en) | Chinese medicine for losing weight and preparation method thereof | |
| CN100509034C (en) | Medicine for treating chronic atrophic gastritis | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN102552657B (en) | Chinese medicinal composition used for treating Newcastle disease of chicken | |
| CN100509041C (en) | Stomach-clearing pill | |
| CN110548109B (en) | Traditional Chinese medicine composition for treating child anorexia and preparation method thereof | |
| CN111249381A (en) | Application of composition in preparation of medicine for preventing and treating constipation | |
| CN104399040A (en) | Drug for treating gastrectasia and preparation method thereof | |
| CN104001070A (en) | Traditional Chinese medicine composition for treating constipation | |
| CN111297974A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating food stagnation | |
| CN116763880B (en) | Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation | |
| CN103736045A (en) | Traditional Chinese medicinal composition for treating superficial gastritis and preparation method thereof | |
| CN108686197A (en) | A kind of Chinese medicine composition that treating gastritis and its application | |
| CN101658613B (en) | Drug for treating infantile chronic indigestion | |
| CN116370592B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver fibrosis as well as preparation method and application thereof | |
| CN109999143B (en) | Traditional Chinese medicine for treating benign tumor proliferative diseases | |
| CN108079152B (en) | Traditional Chinese medicine formula for treating digestive system dysfunction and inflammation | |
| CN100396299C (en) | Medication for treating astriction, and preparation method | |
| CN100387256C (en) | Medicine for treating gastric, anal and intestinal diseases | |
| CN108686003B (en) | Traditional Chinese medicine composition for treating renal insufficiency and proteinuria caused by unknown reasons and preparation and application thereof | |
| CN1217688C (en) | Medicine for treating chronic gastritis and preparing process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |